Theriva Biologics, Inc.
TOVX
$0.32
-$0.02-5.60%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.71M | 1.26M | 11.18M | 1.43M | 1.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.84M | 3.81M | 13.13M | 4.40M | 4.40M |
| Operating Income | -2.84M | -3.81M | -13.13M | -4.40M | -4.40M |
| Income Before Tax | -2.00M | -4.36M | -13.06M | -4.32M | -4.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.00M | -4.36M | -13.06M | -4.32M | -4.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.00M | -4.36M | -13.06M | -4.32M | -4.45M |
| EBIT | -2.84M | -3.81M | -13.13M | -4.40M | -4.40M |
| EBITDA | -2.81M | -3.78M | -13.11M | -4.37M | -4.37M |
| EPS Basic | -0.12 | -0.45 | -1.93 | -1.55 | -1.59 |
| Normalized Basic EPS | -0.06 | -0.24 | -1.21 | -0.97 | -0.95 |
| EPS Diluted | -0.12 | -0.45 | -1.93 | -1.55 | -1.59 |
| Normalized Diluted EPS | -0.06 | -0.24 | -1.21 | -0.97 | -0.95 |
| Average Basic Shares Outstanding | 29.28M | 9.68M | 6.75M | 2.78M | 2.79M |
| Average Diluted Shares Outstanding | 29.28M | 9.68M | 6.75M | 2.78M | 2.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |